BIONTECH SE-ADR (BNTX)
US09075V1026 - ADR
We assign a fundamental rating of 6 out of 10 to BNTX. BNTX was compared to 588 industry peers in the Biotechnology industry. BNTX gets an excellent profitability rating and is at the same time showing great financial health properties. BNTX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
BNTX had positive earnings in the past year.
In the past year BNTX had a positive cash flow from operations.
BNTX had positive earnings in 4 of the past 5 years.
In multiple years BNTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.04%, BNTX belongs to the top of the industry, outperforming 95.89% of the companies in the same industry.
The Return On Equity of BNTX (4.60%) is better than 95.38% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.15%, BNTX belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BNTX is significantly above the industry average of 13.58%.
The 3 year average ROIC (46.52%) for BNTX is well above the current ROIC(3.15%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.04% | ||
| ROE | 4.6% | ||
| ROIC | 3.15% |
ROA(3y)36.53%
ROA(5y)17.56%
ROE(3y)46.06%
ROE(5y)20.59%
ROIC(3y)46.52%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of BNTX (24.36%) is better than 98.46% of its industry peers.
BNTX's Profit Margin has improved in the last couple of years.
BNTX has a better Operating Margin (22.85%) than 97.60% of its industry peers.
The Gross Margin of BNTX (84.29%) is better than 89.38% of its industry peers.
In the last couple of years the Gross Margin of BNTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.85% | ||
| PM (TTM) | 24.36% | ||
| GM | 84.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y98.55%
PM growth 5YN/A
GM growth 3Y-1.33%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BNTX is creating value.
Compared to 1 year ago, BNTX has less shares outstanding
The number of shares outstanding for BNTX has been increased compared to 5 years ago.
BNTX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.66 indicates that BNTX is not in any danger for bankruptcy at the moment.
BNTX has a better Altman-Z score (6.66) than 83.56% of its industry peers.
BNTX has a debt to FCF ratio of 0.05. This is a very positive value and a sign of high solvency as it would only need 0.05 years to pay back of all of its debts.
The Debt to FCF ratio of BNTX (0.05) is better than 97.77% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that BNTX is not too dependend on debt financing.
The Debt to Equity ratio of BNTX (0.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.05 | ||
| Altman-Z | 6.66 |
ROIC/WACC0.45
WACC6.93%
2.3 Liquidity
A Current Ratio of 9.43 indicates that BNTX has no problem at all paying its short term obligations.
With a decent Current ratio value of 9.43, BNTX is doing good in the industry, outperforming 79.11% of the companies in the same industry.
A Quick Ratio of 9.26 indicates that BNTX has no problem at all paying its short term obligations.
BNTX has a better Quick ratio (9.26) than 78.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.43 | ||
| Quick Ratio | 9.26 |
3. Growth
3.1 Past
BNTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -89.63%.
BNTX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 279.64% yearly.
BNTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -77.94%.
BNTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 97.22% yearly.
EPS 1Y (TTM)-89.63%
EPS 3Y279.64%
EPS 5YN/A
EPS growth Q2Q-79.48%
Revenue 1Y (TTM)-77.94%
Revenue growth 3Y99.36%
Revenue growth 5Y97.22%
Revenue growth Q2Q-65.43%
3.2 Future
Based on estimates for the next years, BNTX will show a small growth in Earnings Per Share. The EPS will grow by 1.62% on average per year.
BNTX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.44% yearly.
EPS Next Y-146%
EPS Next 2Y-53.36%
EPS Next 3Y-30.44%
EPS Next 5Y1.62%
Revenue Next Year-34.32%
Revenue Next 2Y-18.41%
Revenue Next 3Y-11.86%
Revenue Next 5Y4.44%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 21.23, the valuation of BNTX can be described as rather expensive.
Based on the Price/Earnings ratio, BNTX is valued cheaper than 96.06% of the companies in the same industry.
BNTX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.20.
The Forward Price/Earnings Ratio is negative for BNTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.23 | ||
| Fwd PE | N/A |
4.2 Price Multiples
BNTX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BNTX is cheaper than 99.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.2 | ||
| EV/EBITDA | -1.63 |
4.3 Compensation for Growth
BNTX has an outstanding profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as BNTX's earnings are expected to decrease with -30.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-53.36%
EPS Next 3Y-30.44%
5. Dividend
5.1 Amount
BNTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIONTECH SE-ADR
NASDAQ:BNTX (4/26/2024, 11:38:50 AM)
87.27
+0.56 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap21.03B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.23 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.04% | ||
| ROE | 4.6% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 22.85% | ||
| PM (TTM) | 24.36% | ||
| GM | 84.29% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.43 | ||
| Quick Ratio | 9.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-89.63%
EPS 3Y279.64%
EPS 5Y
EPS growth Q2Q
EPS Next Y-146%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-77.94%
Revenue growth 3Y99.36%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y